1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Prasterone 6.5 mg (0.50%) Vaginal Insert: new trials by email Literature Review of Prasterone 6.5 mg (0.50%) Vaginal Insert trials Research Report on Prasterone 6.5 mg (0.50%) Vaginal Insert
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert - Hypoactive Sexual Desire Disorder (HSDD) | Phase 3 | Withdrawn | EndoCeutics Inc. | 2018-11-13 | 2020-07-31 | |
| Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | EndoCeutics Inc. | 653 | 2017-10-16 | 2021-04-09 |
Sexual Dysfunction, Physiological (2) · Sexual Dysfunctions, Psychological (2)
EndoCeutics Inc. (2)
United States (2) · Canada (1)
Claude Labrie, M.D., Ph.D. (2) · Leonard R. Derogatis, Ph.D. (1)